Government bills3
- HE 184/2016 vpPassed
Medicine reimbursement cuts and price competition
Savings of 134 million euros will be targeted at medicine reimbursements by increasing price competition between medicines and reducing medicine wastage. At the same time, the reimbursement rate for diabetes medicines other than insulin will be reduced, and the quantity of expensive medicines reimbursed at one time will be decreased.
2 Dec 2016 · 2 votes144 jaa29 ei - HE 106/2015 vpPassed with amendments
Cutting health insurance reimbursements and copayments
Health insurance reimbursements for medicines, travel and medical care will be cut, and the copayments paid by clients will be increased. In addition, temporary additional fees will be imposed on operators in the pharmaceutical sector for 2016.
22 Dec 2015 · 5 votes114 jaa71 ei - HE 91/2018 vpPassed
Streamlining reimbursement decisions for biosimilars
The director of the Pharmaceuticals Pricing Board will be able to decide on the reimbursement status and wholesale price of biosimilar medicines without consideration at a board meeting. At the same time, the composition requirements for the board's expert group will be amended.
21 Nov 2018 · passed without a vote